Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial

- Litwin, Sheldon E., Komtebedde, Jan, Hummel, Scott L., Bugger, Heiko, Boenner, Florian, Hoendermis, Elke, Cikes, Maja, Demers, Catherine, Silva, Guillherme, van Empel, Vanessa, Starling, Randall C., Penicka, Martin, Seidler, Tim, Cutlip, Donald E., Leon, MB, Kitzman, DW, van Veldhuisen, DJ, Shah, SJ, REDUCE LAP-HF investigators and research staff,, Borlaug, Barry A., Winkler, Sebastian, Solomon, Scott D., Eicher, Jean-Christophe, Mazimba, Sula, Khawash, Rami, Sverdlov, Aaron L.

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

- Lyon, Alexander R., Dent, Susan, Stanway, Susannah, Earl, Helena, Brezden-Masley, Christine, Cohen-Solal, Alain, Tocchetti, Carlo G., Moslehi, Javid J., Groarke, John D., Bergler-Klein, Jutta, Khoo, Vincent, Tan, Li Ling, Anker, Markus S., von Haehling, Stephan, Maack, Christoph, Pudil, Radek, Barac, Ana, Thavendiranathan, Paaladinesh, Ky, Bonnie, Neilan, Tomas G., Sverdlov, Aaron L.